Using cell lines with different levels of SST2 expression, e.g., HCT116 (human colon cancer cells), HCT116/SSTR2, AR42J (rat amphicrinic pancreatic cells), and mice bearing SST2 xenografts, improved tumor response and survival rates and long-term efficacy was demonstrated compared to DOTA-octreotate itself [248]. This evidence concerns the gene SSTR2 and neoplasm.